Clinical application of Lishengsu for treatment of leukopenia induced by chemotherapy.
- Author:
Ning-Xi JIANG
1
;
Qiang ZHANG
;
Bai-Hong ZHANG
;
Hong ZHANG
Author Information
1. General Hospital of Lanzhou Military Area of PLA, Lanzhou 730050, China. jiangningxi@sohu.com
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Drug-Related Side Effects and Adverse Reactions;
Female;
Granulocyte Colony-Stimulating Factor;
therapeutic use;
Hemoglobins;
analysis;
Humans;
Leukocyte Count;
Leukopenia;
blood;
chemically induced;
drug therapy;
Male;
Middle Aged;
Neoplasms;
blood;
drug therapy;
Platelet Count;
Recombinant Proteins;
Treatment Outcome
- From:
Journal of Experimental Hematology
2003;11(1):96-98
- CountryChina
- Language:Chinese
-
Abstract:
The efficacy and safety of Lishengsu (a rhG-CSF preparation) were evaluated for treatment of chemotherapy-induced leukopenia. 327 cases of leukopenia with grade I-IV induced by chemotherapy were subcutaneously administered at 2.5 - 5.0 micro g/(kg x d) of Lishengsu, and hemogram and the side effects were observed. The results showed that Lishengsu had satisfactory effect to cure leukopenia after chemtherapy, with an effective rate of 99.4% (325/327), the side effects were quite slight. It is concluded that Lishengsu is efficient and safe for patients with leukopenia, and can be used as an adjuvant drug for treatment of leukopenia after chemotherapy.
